Yang et al. revealed that FTO promoted melanoma tumorigenesis and anti-PD-1 resistance and suggest that the combination of FTO inhibition with anti-PD-1 blockade may reduce the resistance to immunotherapy in melanoma (18). This evidence concerns the gene FTO and melanoma.